GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » Gross-Profit-to-Asset %

Lipigon Pharmaceuticals AB (OSTO:LPGO) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lipigon Pharmaceuticals AB's annualized Gross Profit for the quarter that ended in Dec. 2023 was kr0.00 Mil. Lipigon Pharmaceuticals AB's average Total Assets over the quarter that ended in Dec. 2023 was kr30.23 Mil. Therefore, Lipigon Pharmaceuticals AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


Lipigon Pharmaceuticals AB Gross-Profit-to-Asset % Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Gross-Profit-to-Asset % Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 101.48 46.37 14.24 - 73.88

Lipigon Pharmaceuticals AB Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 279.53 4.61 -

Competitive Comparison of Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset % falls into.



Lipigon Pharmaceuticals AB Gross-Profit-to-Asset % Calculation

Lipigon Pharmaceuticals AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=16.407/( (10.816+33.602)/ 2 )
=16.407/22.209
=73.88 %

Lipigon Pharmaceuticals AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (26.863+33.602)/ 2 )
=0/30.2325
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Lipigon Pharmaceuticals AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines